Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The merozoite surface protein (MSP) 2 is a vaccine candidate antigen of Plasmodium falciparum that is polymorphic in natural populations. In a prospective cohort study in two coastal populations of Kenya using recombinant proteins derived from the two major allelic types of MSP2, high serum levels of IgG to MSP2 were associated with protection from clinical malaria. This protection was independent of that associated with antibodies to another vaccine candidate antigen (AMA1) in these populations. However, low antibody levels to MSP2 appeared to be associated with increased susceptibility to malaria within people who were parasite negative at the time of serum collection. These data suggest that an MSP2 based vaccine should be designed to induce high level antibody responses against the different MSP2 types present globally in P. falciparum populations and that MSP2 could be combined with other P. falciparum antigens to form a multi-component malaria vaccine.

Original publication




Journal article



Publication Date





4233 - 4246


Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Alleles, Animals, Antibodies, Protozoan, Antigens, Protozoan, Child, Child, Preschool, Cohort Studies, Humans, Immunoglobulin G, Infant, Infant, Newborn, Kenya, Malaria Vaccines, Malaria, Falciparum, Membrane Proteins, Middle Aged, Plasmodium falciparum, Prospective Studies, Protozoan Proteins, Risk Factors